Telix New Drug Application for Prostate Cancer Imaging Product Accepted by US FDA
Telix Pharmaceuticals announces New Drug Application (NDA) for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
Investor Briefing: Telix Pharmaceuticals Limited and China Grand Pharma Partnership
Telix Pharmaceuticals Provides Investor Briefing: Our Asian Future
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market
Telix Pharmaceuticals Limited and China Grand Pharma Announce Strategic Licence and Commercial Partnership for Greater China Market.
Activity Report and Sales Note to Accompany Appendix 4C
Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.
Telix Granted FDA Orphan Drug Designation for Glioma Imaging Agent
Telix Pannounces FDA has granted Orphan Drug Designation (ODD) for O-(2-[18F]fluoroethyl)-L-tyrosine for PET imaging of glioma
Telix Pharmaceuticals Submits New Drug Application to US FDA for Prostate Cancer Imaging Product
Telix Pharmaceuticals submits NDA to US FDA for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11)
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Telix announces it has entered into a strategic collaboration agreement with Varian Medical Systems
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s prostate cancer imaging product
FDA Grants Orphan Drug Designation for TLX102
Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of multiple myeloma.
Telix H1 2020 Results and Company Update Conference Call
Telix will hold an investor conference call to present the Company’s H1 2020 financial results together with an update on Telix’s operations.